These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
127 related articles for article (PubMed ID: 14594020)
21. Efficacy and safety of a salvage regimen based on tipranavir, enfuvirtide and three nucleoside analogues in HIV1 infected patients with clinical progression: 96-week evaluation. Sozio F; Polilli E; D'Annunzio M; Falconi L; Di Masi F; Tontodonati M; Cosentino L; Consorte A; Di Giammartino D; Parruti G Infez Med; 2009 Dec; 17(4):228-35. PubMed ID: 20046103 [TBL] [Abstract][Full Text] [Related]
22. [FDA approved the first of a new class of antiretrovirals for adults and children with advanced HIV infection]. Rev Panam Salud Publica; 2003 Jul; 14(1):57-8. PubMed ID: 12952609 [No Abstract] [Full Text] [Related]
23. Providing antiretroviral therapy for HIV infection. Steinbrook R N Engl J Med; 2001 Mar; 344(11):844-6. PubMed ID: 11248164 [No Abstract] [Full Text] [Related]
24. Three new drugs approved by FDA. Hoyt G Surviv News (Atlanta Ga); 2003; ():13, 20. PubMed ID: 14696579 [No Abstract] [Full Text] [Related]
25. Change in HIV-1 DNA tropism despite virological success in patients receiving an enfuvirtide-based regimen. Charpentier C; Joly V; Ghosn J; Yeni P; Raffi F; Descamps D; Morand-Joubert L J Antimicrob Chemother; 2014 Sep; 69(9):2588-90. PubMed ID: 24816213 [No Abstract] [Full Text] [Related]
26. Running a tightrope: regulatory challenges in the development of antiretrovirals. Naeger LK; Struble KA; Murray JS; Birnkrant DB Antiviral Res; 2010 Jan; 85(1):232-40. PubMed ID: 19665489 [TBL] [Abstract][Full Text] [Related]
27. US FDA approves new class of HIV therapeutics. Robertson D Nat Biotechnol; 2003 May; 21(5):470-1. PubMed ID: 12721558 [No Abstract] [Full Text] [Related]
28. First fusion inhibitor for advanced HIV. Am J Nurs; 2003 Jul; 103(7):64F. PubMed ID: 12877130 [No Abstract] [Full Text] [Related]
30. Sustained HIV RNA suppression after switching from enfuvirtide to etravirine in the early access programme. Loutfy M; Ribera E; Florence E; De Wit S; Castagna A; Ryan R; Hill A; Vanaken H; van Delft Y; Marks S J Antimicrob Chemother; 2009 Dec; 64(6):1341-4. PubMed ID: 19828488 [No Abstract] [Full Text] [Related]
31. [On the path to "e-HAART"? Glimpse at salvage therapy]. MMW Fortschr Med; 2001 Apr; 143 Suppl 1():24-5. PubMed ID: 11373771 [No Abstract] [Full Text] [Related]
32. Anti-HIV drug updates--three drugs on the near horizon. Proj Inf Perspect; 2003 Jan; (35):4-7. PubMed ID: 12647672 [TBL] [Abstract][Full Text] [Related]
36. Phase II begins for T-20. AIDS Patient Care STDS; 1999 Sep; 13(9):567-8. PubMed ID: 10813040 [No Abstract] [Full Text] [Related]
37. T-20: first of a new class of anti-HIV drugs. Hanna L BETA; 1999 Jan; 12(1):7-8. PubMed ID: 11367243 [TBL] [Abstract][Full Text] [Related]
38. Long path to approval. A look back at the road to Fuzeon. GMHC Treat Issues; 2003 Mar; 17(3):1-5. PubMed ID: 12728856 [No Abstract] [Full Text] [Related]
39. New class of medications approved for advance HIV. FDA Consum; 2003; 37(3):5. PubMed ID: 12793380 [No Abstract] [Full Text] [Related]